CN102869789B - 与电传导的射频电流向皮肤的施用相关联的基因标签和基因芯片以及与之相关的方法和处理 - Google Patents
与电传导的射频电流向皮肤的施用相关联的基因标签和基因芯片以及与之相关的方法和处理 Download PDFInfo
- Publication number
- CN102869789B CN102869789B CN201180019773.9A CN201180019773A CN102869789B CN 102869789 B CN102869789 B CN 102869789B CN 201180019773 A CN201180019773 A CN 201180019773A CN 102869789 B CN102869789 B CN 102869789B
- Authority
- CN
- China
- Prior art keywords
- skin
- gene
- radio
- frequency current
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 162
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 132
- 230000008569 process Effects 0.000 title claims description 98
- 238000011282 treatment Methods 0.000 claims abstract description 86
- 108010035532 Collagen Proteins 0.000 claims abstract description 49
- 102000008186 Collagen Human genes 0.000 claims abstract description 49
- 229920001436 collagen Polymers 0.000 claims abstract description 49
- 230000009286 beneficial effect Effects 0.000 claims abstract description 37
- 230000014509 gene expression Effects 0.000 claims abstract description 36
- 241000124008 Mammalia Species 0.000 claims abstract description 26
- 230000004044 response Effects 0.000 claims abstract description 26
- 102000004127 Cytokines Human genes 0.000 claims abstract description 15
- 108090000695 Cytokines Proteins 0.000 claims abstract description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 45
- 239000000523 sample Substances 0.000 claims description 35
- 238000012545 processing Methods 0.000 claims description 33
- 238000001228 spectrum Methods 0.000 claims description 22
- 108020004999 messenger RNA Proteins 0.000 claims description 17
- 230000005855 radiation Effects 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 8
- 238000002493 microarray Methods 0.000 claims description 8
- 230000001815 facial effect Effects 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 205
- 210000001519 tissue Anatomy 0.000 description 39
- 230000008859 change Effects 0.000 description 27
- 206010040954 Skin wrinkling Diseases 0.000 description 18
- 230000006378 damage Effects 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 17
- 210000002615 epidermis Anatomy 0.000 description 13
- 230000032683 aging Effects 0.000 description 11
- 230000003796 beauty Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000002500 effect on skin Effects 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000005336 cracking Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108010014258 Elastin Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000007096 poisonous effect Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 102000016942 Elastin Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 DRT10 Proteins 0.000 description 3
- 235000002673 Dioscorea communis Nutrition 0.000 description 3
- 241000544230 Dioscorea communis Species 0.000 description 3
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 3
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 3
- 102100039065 Interleukin-1 beta Human genes 0.000 description 3
- 208000035753 Periorbital contusion Diseases 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 230000003716 rejuvenation Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004906 toe nail Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102000004363 Aquaporin 3 Human genes 0.000 description 2
- 108090000991 Aquaporin 3 Proteins 0.000 description 2
- 241000239290 Araneae Species 0.000 description 2
- 102100040836 Claudin-1 Human genes 0.000 description 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 2
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 description 2
- 102100033167 Elastin Human genes 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 102100031509 Fibrillin-1 Human genes 0.000 description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 2
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 description 2
- 101000851054 Homo sapiens Elastin Proteins 0.000 description 2
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 description 2
- 101000827746 Homo sapiens Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101000917159 Homo sapiens Filaggrin Proteins 0.000 description 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 2
- 101000976051 Homo sapiens Involucrin Proteins 0.000 description 2
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 2
- 101001046936 Homo sapiens Keratin, type II cytoskeletal 2 epidermal Proteins 0.000 description 2
- 101001056452 Homo sapiens Keratin, type II cytoskeletal 6A Proteins 0.000 description 2
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 2
- 101000687673 Homo sapiens Small integral membrane protein 6 Proteins 0.000 description 2
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 2
- 101000626163 Homo sapiens Tenascin-X Proteins 0.000 description 2
- 102100023913 Involucrin Human genes 0.000 description 2
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 2
- 102100022854 Keratin, type II cytoskeletal 2 epidermal Human genes 0.000 description 2
- 102100025656 Keratin, type II cytoskeletal 6A Human genes 0.000 description 2
- 102100021958 Lysyl oxidase homolog 1 Human genes 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 102100024549 Tenascin-X Human genes 0.000 description 2
- 108010077465 Tropocollagen Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008458 response to injury Effects 0.000 description 2
- 108020000318 saccharopine dehydrogenase Proteins 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LYOKOJQBUZRTMX-UHFFFAOYSA-N 1,3-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxy]-2,2-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxymethyl]propane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)OCC(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F LYOKOJQBUZRTMX-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102100031812 Fibulin-1 Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101001065276 Homo sapiens Fibulin-1 Proteins 0.000 description 1
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000006529 extracellular process Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32563310P | 2010-04-19 | 2010-04-19 | |
| US61/325,633 | 2010-04-19 | ||
| PCT/US2011/033033 WO2011133538A1 (en) | 2010-04-19 | 2011-04-19 | Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102869789A CN102869789A (zh) | 2013-01-09 |
| CN102869789B true CN102869789B (zh) | 2015-09-30 |
Family
ID=44343224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180019773.9A Expired - Fee Related CN102869789B (zh) | 2010-04-19 | 2011-04-19 | 与电传导的射频电流向皮肤的施用相关联的基因标签和基因芯片以及与之相关的方法和处理 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2561092A1 (pt) |
| JP (1) | JP2013527756A (pt) |
| KR (1) | KR20120137407A (pt) |
| CN (1) | CN102869789B (pt) |
| BR (1) | BR112012026870A2 (pt) |
| CA (1) | CA2795671A1 (pt) |
| MX (1) | MX2012012235A (pt) |
| WO (1) | WO2011133538A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9671410B2 (en) | 2011-01-16 | 2017-06-06 | The Procter & Gamble Company | Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin |
| MX2013010977A (es) | 2011-03-31 | 2013-10-30 | Procter & Gamble | Sistema, modelos y metodos para identificar y evaluar agentes dermoactivos eficaces para tratar la caspa/dermatitis seborreica. |
| US20130261024A1 (en) * | 2012-03-30 | 2013-10-03 | The Procter & Gamble Company | System for Identifying Connections Between Perturbagens and Genes Associated with a Skin Hyperpigmentation Condition |
| EP2859486A2 (en) | 2012-06-06 | 2015-04-15 | The Procter & Gamble Company | Systems and methods for identifying cosmetic agents for hair/scalp care compositions |
| JP2015531127A (ja) * | 2012-08-15 | 2015-10-29 | ザ プロクター アンド ギャンブルカンパニー | 皮膚疾患の配列の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法 |
| US10966916B2 (en) | 2014-11-10 | 2021-04-06 | The Procter And Gamble Company | Personal care compositions |
| WO2016077325A1 (en) | 2014-11-10 | 2016-05-19 | The Procter & Gamble Company | Personal care compositions with two benefit phases |
| MX2017006149A (es) | 2014-11-10 | 2017-07-27 | Procter & Gamble | Composiciones para el cuidado personal con dos fases beneficas. |
| EP3697375B1 (en) | 2017-10-20 | 2021-12-01 | The Procter & Gamble Company | Aerosol foam skin cleanser |
| CN111225652A (zh) | 2017-10-20 | 2020-06-02 | 宝洁公司 | 气溶胶泡沫洁肤剂 |
| CN113015904A (zh) | 2018-11-29 | 2021-06-22 | 宝洁公司 | 用于筛选个人护理产品的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006080012A1 (en) * | 2005-01-28 | 2006-08-03 | Syneron Medical Ltd | Device for treating skin |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
| US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5366443A (en) | 1992-01-07 | 1994-11-22 | Thapliyal And Eggers Partners | Method and apparatus for advancing catheters through occluded body lumens |
| DE69322266T2 (de) | 1992-04-03 | 1999-06-02 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| US5458596A (en) | 1994-05-06 | 1995-10-17 | Dorsal Orthopedic Corporation | Method and apparatus for controlled contraction of soft tissue |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5755753A (en) | 1995-05-05 | 1998-05-26 | Thermage, Inc. | Method for controlled contraction of collagen tissue |
| US6241753B1 (en) | 1995-05-05 | 2001-06-05 | Thermage, Inc. | Method for scar collagen formation and contraction |
| US5660836A (en) | 1995-05-05 | 1997-08-26 | Knowlton; Edward W. | Method and apparatus for controlled contraction of collagen tissue |
| US6461378B1 (en) | 1995-05-05 | 2002-10-08 | Thermage, Inc. | Apparatus for smoothing contour irregularities of skin surface |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6228078B1 (en) | 1995-11-22 | 2001-05-08 | Arthrocare Corporation | Methods for electrosurgical dermatological treatment |
| US6350276B1 (en) | 1996-01-05 | 2002-02-26 | Thermage, Inc. | Tissue remodeling apparatus containing cooling fluid |
| JP2002515738A (ja) | 1996-01-23 | 2002-05-28 | アフィメトリックス，インコーポレイティド | 核酸分析法 |
| JP4102031B2 (ja) | 1999-03-09 | 2008-06-18 | サーメイジ インコーポレイテッド | 組織を治療するのための装置および方法 |
| US20020087155A1 (en) * | 1999-08-30 | 2002-07-04 | Underwood Ronald A. | Systems and methods for intradermal collagen stimulation |
| US6702808B1 (en) | 2000-09-28 | 2004-03-09 | Syneron Medical Ltd. | Device and method for treating skin |
| PT1331892E (pt) * | 2000-10-18 | 2006-11-30 | Mattioli Eng Ltd | Método e aparelho para renovação de pele por plasma |
| US6889090B2 (en) | 2001-11-20 | 2005-05-03 | Syneron Medical Ltd. | System and method for skin treatment using electrical current |
| US6662054B2 (en) | 2002-03-26 | 2003-12-09 | Syneron Medical Ltd. | Method and system for treating skin |
| AU2003275471A1 (en) | 2002-10-07 | 2004-05-04 | Palomar Medical Technologies, Inc. | Apparatus for performing photobiostimulation |
| SI22738A (sl) * | 2008-04-11 | 2009-10-31 | Iskra Medical, D.O.O. | Naprava za radiofrekvenčno krožno globinsko terapijo |
-
2011
- 2011-04-19 CN CN201180019773.9A patent/CN102869789B/zh not_active Expired - Fee Related
- 2011-04-19 KR KR1020127026405A patent/KR20120137407A/ko not_active Application Discontinuation
- 2011-04-19 WO PCT/US2011/033033 patent/WO2011133538A1/en active Application Filing
- 2011-04-19 MX MX2012012235A patent/MX2012012235A/es not_active Application Discontinuation
- 2011-04-19 EP EP11718568A patent/EP2561092A1/en not_active Withdrawn
- 2011-04-19 BR BR112012026870A patent/BR112012026870A2/pt not_active IP Right Cessation
- 2011-04-19 CA CA2795671A patent/CA2795671A1/en not_active Abandoned
- 2011-04-19 JP JP2013506231A patent/JP2013527756A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006080012A1 (en) * | 2005-01-28 | 2006-08-03 | Syneron Medical Ltd | Device for treating skin |
Non-Patent Citations (1)
| Title |
|---|
| Affymetrix Genechip bhuman Genome U133 plus 2.0 Array;Affymetrix;《GEO》;20031107;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102869789A (zh) | 2013-01-09 |
| CA2795671A1 (en) | 2011-10-27 |
| EP2561092A1 (en) | 2013-02-27 |
| WO2011133538A1 (en) | 2011-10-27 |
| JP2013527756A (ja) | 2013-07-04 |
| MX2012012235A (es) | 2012-11-23 |
| KR20120137407A (ko) | 2012-12-20 |
| BR112012026870A2 (pt) | 2017-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102869789B (zh) | 与电传导的射频电流向皮肤的施用相关联的基因标签和基因芯片以及与之相关的方法和处理 | |
| Seo et al. | RETRACTED ARTICLE: Skin rejuvenation by microneedle fractional radiofrequency and a human stem cell conditioned medium in Asian skin: a randomized controlled investigator blinded split-face study | |
| JP4739202B2 (ja) | 熱傷、創傷、および関連皮膚疾患の光力学治療のためのシステムおよび方法 | |
| Yadollahpour et al. | Electromagnetic fields in the treatment of wound: a review of current techniques and future perspective | |
| US20050283211A1 (en) | Photomodulation methods and devices for regulating cell proliferation and gene expression | |
| Taub et al. | Treatment of acne scars of skin types II to V by sublative fractional bipolar radiofrequency and bipolar radiofrequency combined with diode laser | |
| US20090317911A1 (en) | System and method for photodynamic cell therapy | |
| Maimon et al. | Transdermal optogenetic peripheral nerve stimulation | |
| JP2017510366A (ja) | 皮膚科的欠陥を治療するためのシステムおよび方法 | |
| Boisnic et al. | Split-face histological and biochemical evaluation of tightening efficacy using temperature-and impedance-controlled continuous non-invasive radiofrequency energy | |
| Li et al. | Toward controlled electrical stimulation for wound healing based on a precision layered skin model | |
| Erkiert‐Polguj et al. | The evaluation of elasticity after nonablative radiofrequency rejuvenation | |
| CN102858265A (zh) | 针对调节哺乳动物皮肤状况的组合的能量和局部用组合物应用 | |
| US20120271219A1 (en) | Combined Energy and Topical Composition Application For Regulating the Condition of Mammalian Skin | |
| Ghasemi et al. | The quantitative investigation of spark plasma on skin parameters with skin elasticity, thickness, density, and biometric characteristics | |
| Boisnic et al. | Ex vivo human skin evaluation of localized fat reduction and anti-aging effect by TriPollar™ radio frequency treatments | |
| Lee et al. | Rejuvenation of photoaged aged mouse skin using high-intensity focused ultrasound | |
| Levenberg et al. | Treatment of wrinkles and acne scars using the TriFractional, a novel fractional radiofrequency technology—clinical and histological results | |
| US20120270743A1 (en) | Genetic Signatures and Gene Chips Associated With Administration of Electrically Conducted Radio Frequency Current to Skin and Methods and Treatments Relating Thereto | |
| Mulholland | Internal and External Radiofrequency Assisted Lipo-Coagulation (RFAL) in the control of soft tissue contraction during liposuction: Part 1 “inside Out” thermal tissue tightening | |
| KR100895548B1 (ko) | 고주파 핸드피스 | |
| Shi et al. | Expression and significance of MMP-7, c-Jun and c-Fos in rats skin photoaging | |
| Boisnic et al. | Ex vivo study of the home-use TriPollar RF device using an experimental human skin model | |
| Min | Effect of carbon dioxide laser (10600nm) on hydroxyproline in mouse skin. | |
| Wirya et al. | IMPROVEMENT OF EFFICACY AND SAFETY PROFILE IN TREATING MULTIPLE ERUPTIVE KELOIDS USING COMBINATION OF ABLATIVE FRACTIONAL CARBON DIOXIDE (CO2) LASER AND INTRALESIONAL INJECTION OF STEROID SUSPENSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1180728 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: SYNERON MEDICAL LTD. Free format text: FORMER OWNER: PROCTER + GAMBLE COMPANY Effective date: 20131209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20131209 Address after: Israel Jacques Nimes Yilite Applicant after: Syneron Medical Ltd. Address before: American Ohio Applicant before: Procter & Gamble Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150930 Termination date: 20180419 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1180728 Country of ref document: HK |